The copper peptide promotes tissue repair, reduces inflammation, and boosts antioxidant defenses by activating helpful genes and suppressing harmful ones
Autoradiography and histopathology confirmed the PET imaging results
Importantly, further investigation to identify early, preclinical CNS involvement during peripheral organ injury and/or failure and systemic inflammation is needed, as this is likely to provide the greatest promise for therapeutic intervention
Read review Dihexa for Autism Spectrum Disorder (ASD) The Campbell rs1858830 MET promoter C-allele autism finding (the strongest mechanistic anchor to Dihexa pharmacology), the January 2026 mGluR5 PET 16-23% lower availability, the December 2025 DAYBUE STIX (trofinetide) Rett approval, the March 2026 FDA leucovorin decision (CFD only, not autism), the 270,701 NHS open referrals breaching NICE NG142, and the ~700,000 UK autistic population